Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22325532 | 0.71 | TSHR (0.39) | SMN1; SMN2CYP1A2CYP2D6PKMTSHR | |
| SCHEMBL28970780 | 0.71 | KMT2A (0.34) | PKMTP53MAPTGAAAKR1B1 | |
| SCHEMBL30361544 | 0.71 | CYP2C9 (0.41) | SMN1; SMN2CYP1A2CYP2D6TSHRCYP2C19 | |
| SCHEMBL22325534 | 0.68 | NFKB1 (0.35) | SMN1; SMN2CYP1A2CYP2D6PKMTSHR | |
| SCHEMBL7420613 | 0.67 | PPARA (0.44) | SMN1; SMN2CYP1A2CYP2D6PKMTSHR | |
| SCHEMBL3380544 | 0.67 | PPARA (0.44) | SMN1; SMN2CYP1A2CYP2D6PKMTSHR | |
| SCHEMBL27679509 | 0.66 | GAA (0.33) | SMN1; SMN2CYP1A2CYP2D6PKMTSHR | |
| SCHEMBL5022990 | 0.66 | HTT (0.43) | SMN1; SMN2TSHRMAPTKDM4EAKR1B1 | |
| SCHEMBL5022994 | 0.66 | GRM7 (0.35) | SMN1; SMN2TSHRCYP2C19TP53MAPT | |
| Bicarbonate SCHEMBL8124381 | 0.65 | GPBAR1 (0.44) | TSHRTP53MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450787-A4 | FORMULATIONS AND METHODS FOR TREATMENT OR AMELIORATION OF INFLAMMATORY CONDITIONS | GALILEO PHARMACEUTICALS INC (US) | 2006-01-25 | — | — | EP | claimed |
| EP-1450787-A2 | FORMULATIONS AND METHODS FOR TREATMENT OR AMELIORATION OF INFLAMMATORY CONDITIONS | Galileo Laboratories, Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003043570-A2 | FORMULATIONS AND METHODS FOR TREATMENT OR AMELIORATION OF INFLAMMATORY CONDITIONS | GALILEO LABORATORIES, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20240051932-A1 | LABILE AND COHERENT REDOX-SILENT ANALOGUES FOR VITAMIN E ENHANCEMENT | HERMAY LABS CORP (US) | 2024-02-15 | — | — | US | disclosed |
| WO-2022087735-A1 | LABILE AND COHERENT REDOX-SILENT ANALOGUES FOR VITAMIN E ENHANCEMENT | HERMAY LABS CORPORATION (CA) | 2022-05-05 | — | — | WO | disclosed |
| US-11129554-B2 | Sweat monitoring and control of drug delivery | UNIVERSITY OF CINCINNATI (US) | 2021-09-28 | — | — | US | disclosed |
| US-20180344221-A1 | SWEAT MONITORING AND CONTROL OF DRUG DELIVERY | UNIV CINCINNATI (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180344222-A1 | SWEAT MONITORING AND CONTROL OF DRUG DELIVERY | UNIV CINCINNATI (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180344223-A1 | SWEAT MONITORING AND CONTROL OF DRUG DELIVERY | UNIV CINCINNATI (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180344224-A1 | SWEAT MONITORING AND CONTROL OF DRUG DELIVERY | UNIV CINCINNATI (US) | 2018-12-06 | — | — | US | disclosed |
| JP-2007277187-A | NEW FAT CELL DIFFERENTIATION INHIBITOR | OCHANOMIZU UNIV | 2007-10-25 | — | — | JP | disclosed |
| EP-1199075-B1 | The use of gamma-CEHC as antioxidants | EISAI R&D MAN CO LTD (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1596857-A2 | CHROMAN-DERIVED ANTI-ANDROGENS FOR THE TREATMENT OF ANDROGEN-MEDIATED DISORDERS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005011658-A2 | CHROMAN-DERIVATED ANTI-ANDROGENS FOR TREATMENT OF ANDROGEN-MEDIATED DISORDERS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-02-10 | — | — | WO | disclosed |
| US-6780886-B2 | ADMINISTERING 2,5,7,8-TETRAMETHYL-2-( BETA-CARBOXYETHYL)-6-HYDROXYCHROMANE, OR 2,7,8-TRIMETHYL-2-(BETA-CARBOXYETHYL)-6-HYDROXYCHROMANE; TREATING ARTERIOSCLEROSIS, DISEASE CAUSED BY OXIDATED LOW DENSITY LIPOPROTEIN | EISAI CO., LTD. (JP) | 2004-08-24 | — | — | US | disclosed |
| WO-2002047680-A9 | USE OF TOCOPHEROL, METABOLITES OR DERIVATIVES THEREOF OR FLAVONOID METABOLITES OR DERIVATIVES THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TISSUE ISCHEMIA | GALILEO LAB INC (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002047680-A2 | USE OF TOCOPHEROL, METABOLITES OR DERIVATIVES THEREOF OR FLAVONOID METABOLITES OR DERIVATIVES THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TISSUE ISCHEMIA | GALILEO LABORATORIES, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
| EP-1199075-A2 | Use of vitamine E metabolites alpha-CEHC and gamma-CEHC as antioxidants | Eisai Co., Ltd. (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-20020040053-A1 | Antioxidant containing vitamin E metabolite | MITSUBISHI-CHEMICAL FOODS CORPORATION (JP) | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040053-A1 | Antioxidant containing vitamin E metabolite | TTPA, TXNRD2, CYP27B1 | SMN1; SMN2 2084/4885CYP1A2 450/4885CYP2D6 652/4885 |
| US-20240051932-A1 | LABILE AND COHERENT REDOX-SILENT ANALOGUES FOR VITAMIN E ENHANCEMENT | TTPA, GPX4, PROC | SMN1; SMN2 3620/4885CYP1A2 359/4885CYP2D6 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.